Enliven Therapeutics develops small molecule drugs, led by an investigational kinase inhibitor for chronic myeloid leukemia. ELVN reports earnings on Wed, Nov 11, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 8 firms (8 buy, 0 hold, 0 sell). In the past 30 days there were 2 dark pool prints.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 19 | HC Wainwright & Co. | Target raised | Buy | |
| Oct 2 | Morgan Stanley | Initiated | Buy | |
| Oct 1 | JP Morgan | Initiated | Buy | |
| Aug 18 | Barclays | Initiated | Buy | |
| Aug 18 | Mizuho | Target raised | Buy |
Whale Options Flow
90DNo whale options trades in ELVN in the last 90 days.
Dark Pool
30DAI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ELVN is in one of them and how their past ELVN trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered ELVN in an article yet. Here's the latest on the wider market.
About Enliven Therapeutics
Enliven Therapeutics is a biopharmaceutical company based in Burlingame, California, that develops small molecule drugs. Its lead candidate, ELVN-001, is a kinase inhibitor being studied for chronic myeloid leukemia, a blood cancer, in patients whose disease has become resistant or intolerant to existing treatments. The company also runs research programs on other targeted therapies aimed at unmet medical needs.
- Headquarters
- Burlingame, CA